Revolutionizing Cancer Care Through Liquid Biopsies
Liquid biopsies, especially plasma-based tests, are transforming cancer care by enabling early detection, guiding targeted therapies, and monitoring disease progression with a simple blood draw. These advances are closing the gap between metastatic and adjuvant treatment approvals, potentially bringing life-saving therapies to patients years earlier.
Our latest whitepaper explores how this powerful, precision-based technology is reshaping oncology from screening to survivorship.
In this whitepaper, you will learn about:
- Early Detection: Identify cancers sooner with blood-based tests like Galleri™, which screens for 50+ cancers with 99.5% specificity
- Precision Treatment: Replace invasive tissue biopsies with genomic profiling that captures tumor complexity
- Real-Time Monitoring: Track treatment response and detect minimal residual disease (MRD) earlier and more accurately
Key Highlights
- MRD Detection: Ultra-sensitive assays detect 1 in 10,000 DNA fragments, reshaping trial design and speeding up approvals
- Companion Diagnostics: FDA-approved plasma tests now guide therapy decisions in lung, breast and other cancers
- Pan-Cancer Screening: Multi-cancer detection tests are moving beyond traditional screening, offering a broader, life-saving approach
Don’t miss out – download your copy of this whitepaper by completing the form.